Janssen Vaccines & Prevention B.v.

Crucell Holland B.v.

Robert H E Friesen

Ronald Vogels

Katarina Radosevic

Antonietta Impagliazzo

Stefan Loverix

Jan Willem Meijberg

Philippe Alard

Mark Throsby

David Adrianus Theodorus Maria Zuijdgeest

Theodorus H J Kwaks

Constantin Adrian Apetri

Marijn Van Der Neut Kolfschoten

Ingrid Van Den Nieuwenhof

Mandy A C Jongeneelen

Theodorus Hendrikus Kwaks

The present disclosure provides influenza hemagglutinin stem domain polypeptides comprising (a) an influenza hemagglutinin HA1 domain that comprises an HA1 N-terminal stem segment, covalently linked by a linking sequence of 0-50 amino acid residues to an HA1 C-terminal stem segment, and (b) an influenza hemagglutinin HA2 domain, wherein on or more amino acids in the HA2 domain have been mutated. Also provided are nucleic acids encoding the polypeptides, compositions comprising the polypeptides and/or nucleic acid molecules, as well as methods of their use, in particular in the detection, prevention and/or treatment of influenza.

Influenza virus vaccines and uses thereof

Described are binding molecules, e.g., human monoclonal antibodies, that bind to influenza virus comprising HA of the H3 subtype, e.g., H3N2, and have a broad neutralizing activity against such influenza virus. Described are polynucleotides encoding the binding molecules, their sequences and compositions comprising the binding molecules and methods of identifying or producing the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis, and/or treatment of influenza virus H3N2 infection. The binding molecules may provide cross-subtype protection, such that infections with H3, H7, and/or H10-based influenza subtypes can be prevented and/or treated.

Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof

Described are binding molecules, such as human monoclonal antibodies, that bind to an epitope in the stem region of hemagglutinin of influenza A viruses of phylogenetic group 1 and group 2, as well as influenza B viruses, and have a broad neutralizing activity against such influenza viruses. Provided are nucleic acid molecules encoding the binding molecules, their sequences, and compositions comprising the binding molecules. The binding molecules can be used, for example, in the diagnosis, prophylaxis, and/or treatment of influenza A viruses of phylogenetic groups 1 and 2, as well as influenza B viruses.

Human binding molecules capable of neutralizing influenza A viruses of phylogenetic group 1 and phylogenetic group 2 and influenza B viruses

The disclosure relates to binding molecules, such as human monoclonal antibodies, that bind to Hepatitis B viruses, and have a broad neutralizing activity against such Hepatitis B viruses. The disclosure further provides nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis and/or treatment of Hepatitis B.

Human binding molecules capable of binding to and neutralizing hepatitis B viruses and uses thereof

Growing community of inventors

Leiden, Netherlands

Robert H E Friesen